Tags

Type your tag names separated by a space and hit enter

Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
Respir Investig 2017; 55(1):24-32RI

Abstract

BACKGROUND

We attempted to clarify whether the presence of anti-aminoacyl-transfer RNA synthetase antibody (anti-ARS Ab) or anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5 Ab) is associated with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease (PM/DM-ILD).

METHODS

We retrospectively investigated 22 patients with PM/DM-ILD (10 positive for anti-ARS Ab and nine positive for anti-MDA5 Ab) for whom antibody analysis of conserved serum was possible. We assessed mortality in the first three months as the therapeutic response in the acute phase and compared changes in clinical data for up to one year considered as the chronic phase. We classified the clinical changes over the year into three groups: Improvement (increased % vital capacity [%VC] or diffusing capacity of the lung for carbon monoxide [%DLCO]≥10 or 15%), deterioration (decreased %VC or %DLCO≥10 or 15%), and no change (remainder of the changes). The extent of abnormality demonstrated by high-resolution computed tomography (HRCT) was scored.

RESULTS

Positivity for anti-MDA5 Ab, but not for anti-ARS Ab, was associated with mortality in the first 3 months. Evaluation of the therapeutic response in the first year showed that positivity for the anti-ARS Ab, but not for the anti-MDA5 Ab, was associated with an improvement in %DLCO and a decline in the serum KL-6 levels. Positivity for the anti-ARS Ab or negativity for anti-MDA5 Ab was associated with a greater decrease in bronchial dilatation as seen by HRCT.

CONCLUSIONS

Anti-ARS and anti-MDA5 Abs are associated with the therapeutic response of PM/DM-ILD.

Authors+Show Affiliations

Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi 77, Kurume, Fukuoka 830-0011, Japan. Electronic address: qu_up_fl_o_wer@yahoo.co.jp.Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi 77, Kurume, Fukuoka 830-0011, Japan. Electronic address: okamoto_masaki@med.kurume-u.ac.jp.Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi 77, Kurume, Fukuoka 830-0011, Japan. Electronic address: kaieda@med.kurume-u.ac.jp.Department of Radiology and Center for Diagnostic Imaging, Kurume University School of Medicine, Asahi-machi 77, Kurume, Fukuoka 830-0011, Japan. Electronic address: kimichan@med.kurume-u.ac.jp.Department of Radiology and Center for Diagnostic Imaging, Kurume University School of Medicine, Asahi-machi 77, Kurume, Fukuoka 830-0011, Japan. Electronic address: ebata_tomohiro@med.kurume-u.ac.jp.Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi 77, Kurume, Fukuoka 830-0011, Japan. Electronic address: motajiri@med.kurume-u.ac.jp.Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi 77, Kurume, Fukuoka 830-0011, Japan. Electronic address: nakamura@med.kurume-u.ac.jp.Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi 77, Kurume, Fukuoka 830-0011, Japan. Electronic address: tominaga_masaki@med.kurume-u.ac.jp.Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi 77, Kurume, Fukuoka 830-0011, Japan. Electronic address: wakasugi_daisuke@kurume-u.ac.jp.Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi 77, Kurume, Fukuoka 830-0011, Japan. Electronic address: kawayama_tomotaka@med.kurume-u.ac.jp.Department of Rheumatology and Clinical Immunology, Nippon Medical School, Sendagi 1-1-5, Bunkyo-ku, Tokyo 113-0022, Japan. Electronic address: kuwanam@nms.ac.jp.Department of Rheumatology and Clinical Immunology, Kyoto University, Yoshidahon-machi, Sakyo-ku, Kyoto 606-8501, Japan. Electronic address: mimorit@kuhp.kyoto-u.ac.jp.Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi 77, Kurume, Fukuoka 830-0011, Japan. Electronic address: ida@med.kurume-u.ac.jp.Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Asahi-machi 77, Kurume, Fukuoka 830-0011, Japan. Electronic address: hoshino@med.kurume-u.ac.jp.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28012490

Citation

Yoshida, Naomi, et al. "Association of Anti-aminoacyl-transfer RNA Synthetase Antibody and Anti-melanoma Differentiation-associated Gene 5 Antibody With the Therapeutic Response of Polymyositis/dermatomyositis-associated Interstitial Lung Disease." Respiratory Investigation, vol. 55, no. 1, 2017, pp. 24-32.
Yoshida N, Okamoto M, Kaieda S, et al. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. Respir Investig. 2017;55(1):24-32.
Yoshida, N., Okamoto, M., Kaieda, S., Fujimoto, K., Ebata, T., Tajiri, M., ... Hoshino, T. (2017). Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. Respiratory Investigation, 55(1), pp. 24-32. doi:10.1016/j.resinv.2016.08.007.
Yoshida N, et al. Association of Anti-aminoacyl-transfer RNA Synthetase Antibody and Anti-melanoma Differentiation-associated Gene 5 Antibody With the Therapeutic Response of Polymyositis/dermatomyositis-associated Interstitial Lung Disease. Respir Investig. 2017;55(1):24-32. PubMed PMID: 28012490.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. AU - Yoshida,Naomi, AU - Okamoto,Masaki, AU - Kaieda,Shinjiro, AU - Fujimoto,Kiminori, AU - Ebata,Tomohiro, AU - Tajiri,Morihiro, AU - Nakamura,Masayuki, AU - Tominaga,Masaki, AU - Wakasugi,Daisuke, AU - Kawayama,Tomotaka, AU - Kuwana,Masataka, AU - Mimori,Tsuneyo, AU - Ida,Hiroaki, AU - Hoshino,Tomoaki, Y1 - 2016/09/30/ PY - 2016/01/20/received PY - 2016/08/06/revised PY - 2016/08/25/accepted PY - 2016/12/26/entrez PY - 2016/12/26/pubmed PY - 2017/8/11/medline KW - Amyopathic dermatomyositis KW - Anti-aminoacyl-transfer RNA synthetase antibody KW - Anti-melanoma differentiation-associated gene 5 antibody KW - Interstitial lung disease KW - Polymyositis/dermatomyositis SP - 24 EP - 32 JF - Respiratory investigation JO - Respir Investig VL - 55 IS - 1 N2 - BACKGROUND: We attempted to clarify whether the presence of anti-aminoacyl-transfer RNA synthetase antibody (anti-ARS Ab) or anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5 Ab) is associated with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease (PM/DM-ILD). METHODS: We retrospectively investigated 22 patients with PM/DM-ILD (10 positive for anti-ARS Ab and nine positive for anti-MDA5 Ab) for whom antibody analysis of conserved serum was possible. We assessed mortality in the first three months as the therapeutic response in the acute phase and compared changes in clinical data for up to one year considered as the chronic phase. We classified the clinical changes over the year into three groups: Improvement (increased % vital capacity [%VC] or diffusing capacity of the lung for carbon monoxide [%DLCO]≥10 or 15%), deterioration (decreased %VC or %DLCO≥10 or 15%), and no change (remainder of the changes). The extent of abnormality demonstrated by high-resolution computed tomography (HRCT) was scored. RESULTS: Positivity for anti-MDA5 Ab, but not for anti-ARS Ab, was associated with mortality in the first 3 months. Evaluation of the therapeutic response in the first year showed that positivity for the anti-ARS Ab, but not for the anti-MDA5 Ab, was associated with an improvement in %DLCO and a decline in the serum KL-6 levels. Positivity for the anti-ARS Ab or negativity for anti-MDA5 Ab was associated with a greater decrease in bronchial dilatation as seen by HRCT. CONCLUSIONS: Anti-ARS and anti-MDA5 Abs are associated with the therapeutic response of PM/DM-ILD. SN - 2212-5353 UR - https://www.unboundmedicine.com/medline/citation/28012490/Association_of_anti_aminoacyl_transfer_RNA_synthetase_antibody_and_anti_melanoma_differentiation_associated_gene_5_antibody_with_the_therapeutic_response_of_polymyositis/dermatomyositis_associated_interstitial_lung_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2212-5345(16)30106-X DB - PRIME DP - Unbound Medicine ER -